News

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...
The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...
Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...
Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...
Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...
The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...
Lenacapavir prevents infection and treats HIV, not a 'cure' HIV is the virus that causes AIDS − a disease in which the immune system is damaged to the point that its ability to resist infection ...
How does lenacapavir compare to other HIV prevention drugs? Pre-exposure prophylaxis, or PrEP, medications are sold as a daily pill under brand names Truvada and Descovy, as well as generic versions.